📰 World Persistence News
World Persistence News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from World Persistence. Real-time updates on events, politics, business and more.
October 20, 2023
The real-world evidence study examined patients with PsA taking secukinumab and ixekizumab, highlighting 80% treatment persistence after 1 year.
December 6, 2022
/PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that data from its robust migraine portfolio will be presented at the 16th European Headache Federation...
September 8, 2022
/PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that new data from its migraine portfolio will be presented at the Migraine Trust International Symposium...
September 8, 2022
AbbVie today announced that new data from its migraine portfolio will be presented at the Migraine Trust International Symposium (MTIS) 2022, taking place in London from September 8-11.
July 5, 2022
The Law mod is available to download now on NexusMods
March 29, 2022
-- AbbVie to present 30 abstracts demonstrating its leadership in neuroscience, including continued migraine treatment research across the spectru...